ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 70 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $95,000 | -41.7% | 88,339 | -8.1% | 0.00% | -50.0% |
| Q2 2022 | $163,000 | -83.5% | 96,110 | -49.6% | 0.00% | -77.8% |
| Q3 2021 | $985,000 | +13.0% | 190,550 | -6.9% | 0.01% | +12.5% |
| Q2 2021 | $872,000 | -41.3% | 204,775 | -26.8% | 0.01% | -46.7% |
| Q1 2021 | $1,486,000 | -1.4% | 279,815 | +0.1% | 0.02% | -11.8% |
| Q4 2020 | $1,507,000 | -4.2% | 279,550 | +41.8% | 0.02% | -26.1% |
| Q3 2020 | $1,573,000 | -23.5% | 197,170 | -4.0% | 0.02% | -17.9% |
| Q2 2020 | $2,057,000 | +45.8% | 205,448 | +63.5% | 0.03% | +154.5% |
| Q1 2018 | $1,411,000 | +103.6% | 125,655 | +21.0% | 0.01% | +120.0% |
| Q4 2017 | $693,000 | -8.1% | 103,816 | +12.7% | 0.01% | 0.0% |
| Q3 2017 | $754,000 | +162.7% | 92,100 | +44.1% | 0.01% | +150.0% |
| Q2 2017 | $287,000 | -14.6% | 63,892 | +4.9% | 0.00% | 0.0% |
| Q1 2017 | $336,000 | +22.2% | 60,896 | -10.5% | 0.00% | 0.0% |
| Q4 2016 | $275,000 | – | 68,024 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |